1
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
Condition(s):Hyperglycemia Drug InducedLast Updated:June 11, 2021Terminated
REMD-477: 9 Clinical Trials
Hide Studies Not Open or Pending
2
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Condition(s):Hyperglycemia Drug InducedLast Updated:November 17, 2021Recruiting
3
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
Condition(s):Type 2 Diabetes; Glucose Tolerance Impaired; Insulin SensitivityLast Updated:December 23, 2021Recruiting
4
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Condition(s):Type 1 Diabetes Mellitus; DiabetesLast Updated:February 7, 2017Completed
5
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
Condition(s):Type1 Diabetes MellitusLast Updated:April 5, 2021Completed
6
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Condition(s):Type 2 Diabetes Mellitus; DiabetesLast Updated:April 10, 2018Completed
7
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
Condition(s):Type 1 Diabetes MellitusLast Updated:July 15, 2022Completed
8
Effects of GRA in Patients With Type 1
Condition(s):Type 1 DiabetesLast Updated:September 28, 2021Recruiting
9
Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
Condition(s):Type 1 DiabetesLast Updated:September 14, 2022Active, not recruiting